The report states revenue grew 12.6% YoY to Rs 892.4 crore with net profit up 53% YoY, and the stock trades at 18.5x FY29E EPS.
Read this note →Eris Lifesciences Limited
NSE ERIS BSE 540596 INE406M01024
0 filings · 0 analysed
1,261.60
-20.64%
over 5 years
-
The report states revenue grew 12.6% YoY to Rs 892.4 crore with net profit up 53% YoY, and the stock trades at 18.5x FY29E EPS.
-
HSIE Results Daily 27 Oct 26 HSIE
The report says Eris's EBITDA grew 7% YoY with sales up 13% YoY, and raised H2FY27 margin guidance to 36%, revising the TP to INR 1,500.
-
Pharma and Healthcare Q2FY27 Preview HSIE
The report expects 13% YoY revenue growth led by India chronic therapies and the Semaglutide launch, naming it among strong performers.
-
The report expects Eris to underperform peers with DF sales growth of 10.4% YoY due to muted therapy performance.
Prices from Yahoo Finance, NSE close, delayed — indicative only, not for dealing. Solid markers sit on the exchange's own timestamp.
Targets, and what happened next
What each house published, and where the price has gone since. Orivam issues no calls of its own and takes no view on these.
| House | Published | Call | Entry | Target | Now | Progress | Standing |
|---|---|---|---|---|---|---|---|
| HDFC Securities | 27 Oct 2026, 06:56 | long | 1,105.20 | 1,500.00 | 1,234.10 | 33% | open by 2027-10-27 |
| HDFC Securities | 07 Oct 2026, 15:25 | long | 1,145.80 | 1,730.00 | 1,234.10 | 15% | open by 2027-10-07 |
Deadlines: 0 stated by the house, the rest set by Orivam’s convention — ten trading days for a technical call, twelve months for a price target. A target with no date cannot be judged, so one has to be chosen.
What the desks said
The report says Eris's EBITDA grew 7% YoY with sales up 13% YoY, and raised H2FY27 margin guidance to 36%, revising the TP to INR 1,500.
Read this note →The report expects 13% YoY revenue growth led by India chronic therapies and the Semaglutide launch, naming it among strong performers.
Read this note →The report expects Eris to underperform peers with DF sales growth of 10.4% YoY due to muted therapy performance.
Read this note →Announcement timeline
No filings stored for this company yet.
Never miss the next one.
Orivam emails what the research desks published each trading morning, attributed and linked to the original notes. Free.
Get the daily brief